© 2021 MJH Life Sciences and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Expert panelists share insight on the current treatment landscape of cervical cancer, locally advanced and metastatic, in light of recent clinical studies and drug approvals.
October 20th 2021
Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.
A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.
October 27th 2021
The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.
Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.
November 3rd 2021
Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.
Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.
November 10th 2021
Looking at the current treatment landscape in metastatic cervical cancer, experts consider the role of frontline chemotherapy and antiangiogenesis therapy.
Considerations for the KEYNOTE-826 trial, which tested pembrolizumab in combination with chemotherapy in patients with metastatic cervical cancer.
November 18th 2021
Experts take a closer look at the data points from KEYNOTE-826 to consider pembrolizumab’s potential role in metastatic cervical cancer management.
Switching its focus to second-line therapy for metastatic cervical cancer, the panel reviews an unmet need of effective therapy in this setting.
November 24th 2021
An overview of second-line immune checkpoint inhibitor use in patients with relapsed or refractory metastatic cervical cancer.
Panelists reflect on the potential for immune checkpoint inhibition to become a frontline option in metastatic cervical cancer, and what that means for the second-line setting.
December 2nd 2021
Shared insight on the approval of tisotumab vedotin, an antibody-drug conjugate, in the second-line setting of metastatic cervical cancer.
Considerations for adverse event management with tisotumab vedotin use in patients with metastatic cervical cancer.